MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11

Nature Communications

Volumn 4, Issue , 2013, Pages

  Bockhorn, Jessica ^a,b   Dalton, Rachel ^a   Nwachukwu, Chika ^b   Huang, Simo ^a   Prat, Aleix ^c,f   Yee, Kathy ^a   Chang, Ya Fang ^a   Huo, Dezheng ^b   Wen, Yujia ^b   Swanson, Kaitlin E ^a   Qiu, Tyler ^a   Lu, Jun ^d   Young Park, Seo ^b   Eileen Dolan, M ^b   Perou, Charles M ^c   Olopade, Olufunmilayo I ^b   Clarke, Michael F ^e   Greene, Geoffrey L ^a   Liu, Huiping ^a,e  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 11; MICRORNA; MICRORNA 30C; TRANSCRIPTION FACTOR GATA 3; TUMOR MARKER; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; DOXORUBICIN; GATA3 PROTEIN, HUMAN; IL11 PROTEIN, HUMAN; MIRN30 MICRORNA, HUMAN; PROTEIN TYROSINE KINASE; TWF1 PROTEIN, HUMAN;

CANCER; CHEMOTHERAPY; MOLECULAR ANALYSIS; RNA; TUMOR;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; TRANSCRIPTION REGULATION; ANIMAL; BREAST TUMOR; CELL SURVIVAL; CLUSTER ANALYSIS; CYTOSKELETON; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REPRESSION; GENETICS; METABOLISM; MOUSE; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CLUSTER ANALYSIS; CYTOSKELETON; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GATA3 TRANSCRIPTION FACTOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-11; MICE; MICROFILAMENT PROTEINS; MICRORNAS; PROGNOSIS; PROTEIN-TYROSINE KINASES; REAL-TIME POLYMERASE CHAIN REACTION; SUPPRESSION, GENETIC; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MLCS; MLOWN;

EID: 84879177004     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms2393     Document Type: Article

References (36)

1. Lu, J. et al. MicroRNA expression profiles classify human cancers. Nature 435, 834-838 (2005). (Pubitemid 40839735)
2. Creighton, C. J. et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl Acad. Sci. USA 106, 13820-13825 (2009).
3. Singh, A. & Settleman, J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741-4751 (2010).
4. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297 (2004).
5. Fabian, M. R., Sonenberg, N. & Filipowicz, W. Regulation of mRNA translation and stability by microRNAs. Annu. Rev. Biochem. 79, 351-379 (2010).
6. Buffa, F. M. et al. microRNA-Associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res. 71, 5635-5645 (2011).
7. Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160-1167 (2009).
8. Prat, A. et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12, R68 (2010).
9. Rodriguez-Gonzalez, F. G. et al. MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Res. Treat. 127, 43-51 (2011).
10. Guo, H., Ingolia, N. T., Weissman, J. S. & Bartel, D. P. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466, 835-840 (2010).
11. Antonov, A. V., Dietmann, S., Wong, P., Lutter, D. & Mewes, H. W. GeneSet2miRNA: finding the signature of cooperative miRNA activities in the gene lists. Nucleic Acids Res. 37, W323-W328 (2009).
12. Meacham, C. E., Ho, E. E., Dubrovsky, E., Gertler, F. B. & Hemann, M. T. In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. Nat. Genet. 41, 1133-1137 (2009).
13. Palmgren, S., Vartiainen, M. & Lappalainen, P. Twinfilin, a molecular mailman for actin monomers. J. Cell Sci. 115, 881-886 (2002). (Pubitemid 34257373)
14. Kokkinos, M. I. et al. Vimentin and epithelial-mesenchymal transition in human breast cancer-observations in vitro and in vivo. Cells Tissues Organs 185, 191-203 (2007). (Pubitemid 46957486)
15. Sommers, C. L. et al. Loss of epithelial markers and acquisition of vimentin expression in adriamycin-and vinblastine-resistant human breast cancer cell lines. Cancer Res. 52, 5190-5197 (1992).
16. Ojala, P. J. et al. The two ADF-H domains of twinfilin play functionally distinct roles in interactions with actin monomers. Mol. Biol. Cell 13, 3811-3821 (2002). (Pubitemid 35398550)
17. Poukkula, M., Kremneva, E., Serlachius, M. & Lappalainen, P. Actin-depolymerizing factor homology domain: a conserved fold performing diverse roles in cytoskeletal dynamics. Cytoskeleton (Hoboken) 68, 471-490 (2011).
18. Helfer, E. et al. Mammalian twinfilin sequesters ADP-G-actin and caps filament barbed ends: implications in motility. EMBO J. 25, 1184-1195 (2006).
19. Paavilainen, V. O. et al. Structural basis and evolutionary origin of actin filament capping by twinfilin. Proc. Natl Acad. Sci. USA 104, 3113-3118 (2007). (Pubitemid 46364122)
20. Pu, Y. S. et al. Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells. Prostate 60, 120-129 (2004).
21. Duan, Z., Feller, A. J., Penson, R. T., Chabner, B. A. & Seiden, M. V. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin. Cancer Res. 5, 3445-3453 (1999).
22. Vega, M. I. et al. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene 23, 3530-3540 (2004). (Pubitemid 38658419)
23. Putoczki, T. & Ernst, M. More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer. J. Leukoc. Biol. 88, 1109-1117 (2010).
24. Medjkane, S., Perez-Sanchez, C., Gaggioli, C., Sahai, E. & Treisman, R. Myocardin-related transcription factors and SRF are required for cytoskeletal dynamics and experimental metastasis. Nat. Cell Biol. 11, 257-268 (2009).
25. Liu, H. et al. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc. Natl Acad. Sci. USA 107, 18115-18120 (2010).
26. Wasserman, W. W. & Sandelin, A. Applied bioinformatics for the identification of regulatory elements. Nat. Rev. 5, 276-287 (2004). (Pubitemid 38435623)
27. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
28. Gibson, R. J. et al. Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig. Dis. Sci. 47, 2751-2757 (2002). (Pubitemid 35471617)
29. Posern, G. & Treisman, R. Actin together: serum response factor, its cofactors and the link to signal transduction. Trends Cell Biol. 16, 588-596 (2006). (Pubitemid 44636222)
30. Asselin-Labat, M. L. et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol. 9, 201-209 (2007).
31. Hoch, R. V., Thompson, D. A., Baker, R. J. & Weigel, R. J. GATA-3 is expressed in association with estrogen receptor in breast cancer. Int. J. Cancer 84, 122-128 (1999). (Pubitemid 29133821)
32. Kouros-Mehr, H., Slorach, E. M., Sternlicht, M. D. & Werb, Z. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 127, 1041-1055 (2006). (Pubitemid 44792255)
33. Hu, Z. et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7, 96 (2006).
34. Prat, A. et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12, R68 (2011).
35. Huo, D. et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J. Clin. Oncol. 27, 4515-4521 (2009).
36. Team, R.D.C.R. A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, Vienna, Austria, 2011).